<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572660</url>
  </required_header>
  <id_info>
    <org_study_id>Reda 012357</org_study_id>
    <secondary_id>2018-001063-23</secondary_id>
    <nct_id>NCT03572660</nct_id>
  </id_info>
  <brief_title>Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM</brief_title>
  <acronym>DCM-Support</acronym>
  <official_title>Phase II Study Assessing the Combined Use of Autologous Bone Marrow Derived Mononuclear Cells and G-csf With Percutaneous Circulatory Assistance in the Treatment of Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DCM SUPPORT study is a single centre, single arm study evaluating the change in left&#xD;
      ventricular ejection fraction with the combines use of bone marrow derived stem cells and&#xD;
      G-CSF with a percutaneous circulatory assistance for the treatment of dilated cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DCM SUPPORT study is a single centre, single arm, phase II pilot study. The primary&#xD;
      endpoint will be a change in LVEF from baseline measured by a CT scan of the heart at 3&#xD;
      months. The secondary endpoints include change in LVEF from baseline measured by a CT scan of&#xD;
      the heart at 12 months, in-hospital procedural related morbidity / mortality and assessment&#xD;
      of major adverse cardiac events (MACE; death, heart attack, need for repeat heart&#xD;
      revascularisation), change in exercise capacity and NYHA class at 3 months and 12 months&#xD;
      respectively. The NYHA classification is a quantitative way of assessing a patient's heart&#xD;
      failure symptoms. It places patients into one of four categories (I - IV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm intervention study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction Imaging</measure>
    <time_frame>Baseline to 3 Months</time_frame>
    <description>Change in Left Ventricular Ejection Fraction on Cardiac CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Left Ventricular Ejection Fraction on Cardiac CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters</measure>
    <time_frame>Baseline to 1,3 and 12 months</time_frame>
    <description>Change in NT-proBNP, troponin, creatine kinase, renal function and CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>3 &amp; 12 months</time_frame>
    <description>MACE endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity 6 minutes walk test</measure>
    <time_frame>Baseline to 3 &amp; 12 months</time_frame>
    <description>Change distance covered measured in meters during a 6 minutes walking test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NHYA classfication</measure>
    <time_frame>Baseline to 3 and 12 months.</time_frame>
    <description>Change in heart failure symptoms as measured on NHYA classification as assessed by physician.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>BMMNC intervention arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone marrow derived mononuclear cells and G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bone marrow derived mononuclear cells and G-CSF</intervention_name>
    <description>Intra-coronary infusion</description>
    <arm_group_label>BMMNC intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of dilated cardiomyopathy under the supervision of&#xD;
             a physician or a heart failure nurse specialist.&#xD;
&#xD;
          -  NYHA class III or IV symptoms despite having received optimal medical therapy and&#xD;
             appropriate device therapy, as per clinical guidelines for an interval of at least 3&#xD;
             months.&#xD;
&#xD;
          -  No other treatment options available as part of current best standard care.&#xD;
&#xD;
          -  LVEF ≤30% on the cardiac CT scan performed as part of the screening phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NYHA I-II.&#xD;
&#xD;
          -  Documented latest ejection fraction &gt;30% (any imaging modality)&#xD;
&#xD;
          -  Congenital heart disease.&#xD;
&#xD;
          -  Clinically significant valvular heart disease.&#xD;
&#xD;
          -  Patients who are not suitable for a Percutaneous Mechanical Support Device (E.g.&#xD;
             unsuitable femoral artery anatomy, unable able to lie flat for prolonged time to&#xD;
             accommodate the stem cell infusion &amp; presence of LV thrombus)&#xD;
&#xD;
          -  Weight of patient that exceeds the maximum limit of the cardiac catheter laboratory&#xD;
             table / CT scanner.&#xD;
&#xD;
          -  Cardiomyopathy 2o to a reversible cause that has not been treated e.g. thyroid&#xD;
             disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium&#xD;
             toxicity &amp; chronic uncontrolled tachycardia.&#xD;
&#xD;
          -  Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's&#xD;
             progressive muscular dystrophy.&#xD;
&#xD;
          -  Previous cardiac surgery.&#xD;
&#xD;
          -  Contra-indication for bone marrow aspiration.&#xD;
&#xD;
          -  Known active infection at time of randomisation.&#xD;
&#xD;
          -  Positive virology tests.&#xD;
&#xD;
          -  Chronic inflammatory disease requiring on-going medication.&#xD;
&#xD;
          -  Concomitant disease with a life expectancy of less than one year&#xD;
&#xD;
          -  Follow-up impossible (no fixed abode, etc.)&#xD;
&#xD;
          -  Neoplastic disease without documented remission within the past 5 years.Patients on&#xD;
             renal replacement therapy.&#xD;
&#xD;
          -  Subjects of childbearing potential unless βHCG negative and are on adequate&#xD;
             contraception during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Mathur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts &amp; The London NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Mathur</last_name>
    <phone>0203 765 8715</phone>
    <email>anthony.mathur@bartshealth.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessry Veerapen</last_name>
    <phone>0203 765 8708</phone>
    <email>dj.veerapen@bartshealth.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessry Veerapen</last_name>
      <phone>0203 765 8708</phone>
      <email>dj.veerapen@bartshealth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mohsin Hussain</last_name>
      <phone>0203 765 8704</phone>
      <email>mohsin.hussain2@bartshealth.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell</keyword>
  <keyword>circulatory support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

